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Glucocorticoids (anti-inflanunatory steroids) are very 
potent inhibitors of mouse skin tumor promotion in-
duced by 12-0-tetradecanoylphorbol-13-acetate (TPA). 
This report describes a high-affinity, limited-capacity 
binding component which specifically interacts with glu-
cocorticoids and which is identified as a glucocorticoid 
(GC) receptor present in the cytosol of adult mouse epi-
dermis. Also described is the effect of a single application 
of TP A and other hyperplasiogenic agents on the level 
of epidermal cytosol GC receptor_After treatment with 
acetone the epidermal GC receptor level was 0.38 pmol! 
mg cytosol protein, whereas after application ofTPA (4 
/Lg) there was a time-dependent transient decrease in the 
level of GC receptor (39% of control 24 hr after TP A) 
followed by an increase (55% and 66% of control 48 and 
72 hr, respectively, after TPA). Hyperplasiogenic agents 
such as mezerein and ethylphenylpropiolate were also 
effective in causing a reduction in the level of epidermal 
cytosol GC receptor level, but weak tumor promoters 
such as phorbol dibenzoate and 4-0-methyl TPA were 
less effective than TP A. Therefore, there is a good cor-
relation among agents which induce epidermal hyper-
plasia and agents which cause a reduction in epidermal 
cytosol GC receptor levels. The functional significance 
of the decrease in receptor level is discussed. 
Glucocorticoid (GC) hormones have varied physiologic and 
biochemical effects in target tissues [1]. They are known to be 
potent inhibitors of DNA synthesis and cell proliferation in 
lymphoid cells [2], fibroblasts [3], and skin [4-6]. GCs, both 
natUJ'aJ and synthetic, inhibit mouse skin carcinogenesis and 
tumor promotion induced by 12-0-tetradecanoylphorbol-13-
acetate (TPA) [6-10]. One of their major effects on tumor 
promotion is the inhibition of TP A-induced epidermal hyper-
plasia and inflammation [6,10,11]. Not only do exogenous GCs 
influence skin tumor promotion, but endogenous GCs appeal' 
to influence tumo.!: promotion as well. Train in [8] observed that 
adrenalectomy enhances tumor promotion induced by croton 
oil. 
The response of a target tissue to steroid hormones is initiated 
by binding of steroid hormones to specific cytoplasmic recep-
tors, followed by translocation of steroid-hormone receptor 
complexes to the nucleus, where they bind to acceptor sites on 
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chromatin, thus stimulating genetic transcript ion [12]. The 
purpose of this investiga tion was to determine whether a GC 
binding component (receptor) was present in ad ult mouse epi-
dermis through which exogenous GCs may act to inhibit tumor 
promotion and through which endogenous hormones may pre-
vent a maximum response. We also determined whether TPA 
and other hyperplasiogenic agents had an effect on the level of 
epidermal cytosol GC receptor. In this paper evide nce is pro-
vided to support the hypotheses that GC receptors are present 
in epidermal cells and that the number of receptors may be 
important in epidermal cell proliferation. 
MATERIALS AND METHODS 
A n.imals a.n.d Treatment 
SEN CAR male and female mice were bred and maintained in the 
Biology Division, Oak Ridge National Laboratory. Mice 7 to 8Y, weeks 
old and in the resting phase of their hail' cycle were used. They were 
shaved at least 24 hr prior to treatment and were treated between 8:00 
and 11:00 AM to eliminate possible alterations due to the circadian 
rhythm. Ten mice per group were used for binding assays. Acetone (0.2 
ml) or experimental compound dissolved in 0.2 ml acetone was applied 
to the dorsal skin of the mice. 
Materials 
[1,2-"H]-Dexamethasone (Dex) (sp act 25 Ci/ mmol) was obtained 
from Amersham (Arlington Heights, illinois), and unlabeled steroids 
were from Sigma (St. Louis, Missouri). TPA, phorbol-12,13-dibenzoate, 
and mezerein were obtained from Dr. Peter Borchert (U niversity of 
Minnesota, Minneapolis). Ethylphenylpropiolate (EPP) was purchased 
from Aldrich Chemical Co. (Milwaukee, Wisconsin), and [methyl-"H]-
thymidine (sp act 6 Ci/ mmol) was (i'om New England Nuclear (Boston, 
Massachusetts). 
Preparation of Epidermal Cytosol 
At. various t imes fo llowing treatment, the mice were killed by CO~ 
asphyxiation, and the dorsa l skin was removed . The epidermis was 
scraped from the skin of 10 mice using a razor blade [13] and was put 
in to ]0 ml of TEDK buffer (10 mM Tris-HCl, 1.5 lllM EDTA, 0.5 mM 
dithiothreitol, 50 mM KCI) and homogenized (3 x 20 sec) in a Polytron 
homogenizer (Brinkman Instruments, Westbury, New York). The epi-
dermis prepared by this method is not contaminated by dermis [13). 
The homogenate was filtered through 2 layers of gauze and centrifuged 
at 30,000 x g for 70 min. T he supernatant was carefully removed to 
avoid lipid contamination. ALI preparative procedures were carried out 
at 0-2°C_ 
R ecepl.or Assay 
Receptor assays were caJ'l'ied out at 0° in an ice-water bath. 
[1 ,2-"H]-Dex in concentrations of 1-100 nM was incubated with 0.3 ml 
epidermal cytosol for 3 hr in 10 X 75 mm polypropylene tubes. Non-
specific binding was determined in the presence of 100-fold excess 
unlabeled Dex. Unbound ["H]-Dex was removed by addition of 0.25 ml 
charcoal-dextran (2.5 g Norit A + 0.25 g Dextran 1'-500 in 100 ml 
TEDK buffer). The samples were centrifuged at 800 x g for 15 min; the 
supernatant was decanted in to scin tillation vials, scintillation Ouid 
(toluene-Liquifluor-Triton X-lOO) was added, and the samples were 
counted. For determination of specific binding, nonspecific binding was 
subtracted from tota l binding. Receptor concentrat.ion (expressed as 
pmol/mg cytosol protein) and dissociation constants were estimated by 
the method of Scatchard [14]. Protein concentrations were determined 
by the method of Lowry et al [15). 
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Incorporation of ('H) . Thymidine into Epiderm.al DNA of TPA·Dex 
Treated Mice 
SEN CAR mice were treated topically with 4 /Lg TPA alone or in 
combination with 25 /.Ig Dex. Twenty-four hours after the application 
of TPA, the mice were injected with 30 /LCi ["H)-thymidine; t hey were 
killed by cervical dislocation 30 min after the injection. DNA hydroly-
sates were prepared from the epidermis according to a modified 
Schmidt-Thannhauser pl"Ocedure described by S laga et al [16). The 
specific activity of DNA was expressed as cpm! /.Ig DNA (counting 
e fficiency was 33%) and reported as percent of specific activity for the 
TPA-treated mice. 
RESULTS 
Binding of [ 3Hl-Dex in Epidermal Cytosol 
It was impracticable to adrenalectomize the large number of 
animals required for this study; therefore, an attempt was made 
to measme CH]-Dex binding by means of a steroid exchange 
assay at elevated temperatmes. At 18°C maximum binding 
occurred between 50 and 60 min (Fig 1). However, the amount 
of binding at 18°C was below that which occurred at 0° for 180 
min. At 25°C specific binding peaked in less time and at a lower 
level than at 18°C. Although not shown here, there was no 
significant increase in binding at 0° if incubation was continued 
for 4 hr, but there was a decrease of 55% if binding was 
continued for 24 hr. Thus, the optimum incubation conditions 
for measuring the binding of CH]-Dex in epidermis from intact 
animals was at 0° for 180 min. 
Fig 2 shows the effect of varying protein concentrations on 
the binding of ["H]-Dex in epidermal cytosol. A linear relation-
ship between specific binding and protein concentration was 
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FIG 1. Effect of t ime and temperature on the binding of ["H]-Dex in 
e pidermal cytosol from untreated mouse skin. Binding at 0° (e); l8°C 
(0 ); 25°C (6 ). Epidermal cytosol was incubated with 10 nM ["H]-Dex. 
U nbound steroid was extracted by the chru'coal-dextran method. 
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FIG 2. B ind il1g of ["H]-Dex in epidermal cytosol as a function of the 
protein content in the assay tubes. Epidermal cytosol was prepru'ed 
from skin 24 hI' after application of 0.2 ml acetone (0 ) or 4 /Lg TPA 
(e). ["H]-Dex concentration, 20 nM. Unbound steroid was extracted by 
t he charcoal-dextran method as described in Materials and Methods. 
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FIG 3. Binding of ["H]-Dex in epidermal cytosol 24 hr after treat-
ment of mouse skin with 0.2 ml acetone (A) or 4 /Lg TPA (B). Total 
binding (0); specific binding (e); nonspecific binding (0 ). Insets ru'e 
Scatchru'd plots. 
TABLE L [nhibit;oll of {'H}·De.,· bill ding ;11 epidermal cy tosol 
Inhibitor 
Dexamethasone 
Triamcinolone acetonide 
CorLicost.erone 
Prednisolone 
Co rtisol 
d-Aldosterone 
Reichslein's subs tance "S" 
Progesterone 
Estradiol-1 7,8 
TPA 
% of Control" 
lOx ["H)·Dex 
14 
5 
22 
31 
45 
77 
80 
100.0 
100.0 
98 (JOOx) 
lOOx ["H)-Dex 
o 
o 
J 
3 
7 
19 
23 
42 
92 
98 (JOOOx) 
" dpm specifically bound by use of lOOx unlabeled Dex to determine nonspe· 
cific binding. % of control is dpm specifically bound in presence of inhibitor + 
dpm specifi cally bound without inhibitor X 100. The concentration of CH)-Dex 
in the assay was 10 nM. The concentration of inhibitors was 100 nM (lOx) or 1 
I'M (lOOX). The concentration of TPA was J I'M (100X) or 10 I,M (lOOOX). 
observed in epidermal cytosol from both acetone- and TP A-
treated mice. The amount of protein in incubation mixtures 
ranged from 0.5-1.2 mg and from 0.9-2.5 mg for acetone-treated 
control and experimental mice, respectively. 
In Fig 30. and b the results from typical binding assays are 
shown. Binding of [3H]-Dex in epidermal cytosol from both 
control and TPA-treated mice was saturable. The regression 
lines of the Scatchard plots were linear, thus indicating the 
presence of only one binding component. The dissociation 
constants Kd ) were estimated to be 8.94 X 10- 9 M and 5.67 x 
lO- H M for control and TPA-treated mice, respectively. 
The specificity of the Dex binding component is presented in 
Table I. GCs, both natural and synthetic, competed with CH]-
Dex for sites on the binding component; progesterone and 
estradiol-17,8 were less competitive. Table I also shows that 
TPA, when added to the incubation mixtme at 100- and 1000-
fold the concentration of CH]-Dex, did not inhibit the binding 
of ["H]-Dex. 
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The above results demonstrate that the Dex binding com-
ponent is saturable, has a high affinity, and specifically binds 
GCs. Therefore this binding component satisfies the require-
ment for a GC receptor. 
Effect of TPA on the GC Receptor Level in Epidermal 
Cytosol 
SEN CAR mice were treated topically with either 0.2 ml 
acetone or 4 jlg TP A in 0.2 ml acetone. Table II summarizes the 
results of the effect of TP A on GC receptors in epidermal 
cytosol. The concentration of receptors and the dissociation 
constants were similar in controls 4-72 hI' after application of 
acetone, thus these data were combined to calculate a single 
control value. In TP A-treated mice the concentration of GC 
receptors was decreased by 53% relative to control 4 hr after 
application of the tumor promoter. At 6 hr after TPA applica-
tion, the GC receptor level was reduced by 63% and remained 
at this level until 24 hr after TP A. At 48 hr after TP A, GC 
receptor levels were beginning to return to normal (45% reduc-
tion), and by 72 hr they were reduced by only 34%. Therefore, 
although GC receptor levels were reduced to less than 50% of 
control 4-24 hr after TPA application, a definite recovery was 
observed by 48 hr. 
The dissociation constant of epidermal GC receptors in TPA-
treated skin varied; however, a trend was observed. At 4 and 6 
hr after TP A application the dissociation constant was in-
creased, followed by a decrease at 24 hr and a return to control 
values at 48 and 72 hr. These variations are not statistically 
different. 
In Table III the effect of various doses of TP A on the 
reduction of epidermal GC receptor levels is shown. A dose-
dependent relationship was observed: 8 jlg of TP A was more 
effective in reducing GC receptor levels than eith er 2 or 4 jlg. 
The dissociation constants were similar when 2 or 4 jlg TP A 
were applied. Application of 8 jlg caused a 2-fold increase in the 
dissociation constant; however, the deviations were so large 
that the differences were not statistically significant when com-
pared with either controls or the lower doses of TP A. 
Effect of Dex on the Incorporation of { lHJ-Thymidine into 
Epidermal DNA of TPA -Treated Shin 
Table II shows that epidermal GC receptor levels were mark-
edly reduced after application of TP A to the skin, which sug-
gests that the epidermis may be less sensitive to GCs. If the 
epidermis is less sensitive, Dex should be more effective in 
TABl"E II. Effect of TPA on g Lucocorticoid receptors in SENCAR 
m.ouse epide;-m.is 
Treatment, Time a fte r Receptor conc" 'Ii of . 
dose appiication
l
' (pmol/ mg pro- 0 to clon-
(hr) tein) 10 
Aceto ne. 0.2 4-72 (1 5) 0.38 ± 0.016 
ml 
TPA,4I'g 4 (3) O. I 7 ± 0.038' 47 
TPA ,4I'S 6 (5) 0.14 ± 0.017' 37 
TPA,4 I'g 24 (4) 0.15 ± 0.009" 39 
TPA,4 I'S 48 (3) 0.21 ± 0.016 55 
TPA,4I'g 72 (3) 0.25 ± 0.033 66 
(I Number of ex periments in parentheses. 
"Mean ± SE. 
DissociaLion COIl -
stant" K'I 
9.6 ± 0.4 1 X 10 II 
13.2 ± 2.02 X )0- 0 
12.8 ± l.91 X 10- 1J 
6.9 ± 0.80 X 10-1) 
11.0 ± 1.40 X )0- " 
9.2 ± 1.33 x 1O- 1J 
" p <: 0.001 for cont rol vs TPA-treated (Student's t -test). 
TAIlLE II1 . Effect of dose of TPA on glucocorticoid receptor in SENCAR 
mouse epiderm.is 24 hr after application 
Dose of Rece ptor conc'" b (pmol!mg % of con-
TPA (I'g) protein) trol Dissociation constant," K" 
None 
2 
4 
8 
" M ea n ± SE . 
0.38 ± 0.0\6 (1 5)" 
0.18 ± 0.005 (2) 
0.1 5 ± 0.009 (4) 
0.11 ± 0.014 (2) 
47 
39 
29 
,. Number of experime nts is shown in pa rentheses. 
9.6 ± 0.4 1 X 10-" 
10.4 ± 0.30 X 10-» 
6.9 ± 0.80 x 10- " 
21.1 ± 6.44 X 10- » 
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TAULI, IV. Effect of Oe:< (25 1-'15) on DNA synthe.,is ill epiderm.is of TPA -I.rcated 
Sllin. 
Primary treat-
ment 
TPA (41'S) 
TPA (4/1g) 
TPA (4 I'i~) 
.. M ean ± SE. 
Secondary t reatment 
Dex (25 I'g). same ti me 
D ex (25 I'g). 6 hr later 
Spec ific activity" ' " % inhibi-
(cpm/ I'g DNA) t ion " 
39.9 ± 2.97 (6) '-
22.9 ± 1.20 (6) 
29.7 ± 2.24 (8) 
o 
42 
25 
"Specific activity of DNA 24 hr after primary treatment, expressed as perce nt 
inhibi t ion of ON A synthesis in rela tion to pril11aJ-y treatme nt alo ne. 
' Total number of groups (2 mice/group) in two experiments: p <: 0.05 lor all 
combinations (Student's t-test). 
TABLE V . Effect of m.ezerein, EPP, and nOl/promoting phorbol esters on 
glucocorticoid receptors in S ENCAR m.ou .. 'e epiderm.is 24 hI' after applicatiol/ 
" M ean ± SE. There were 15 experiments for the control grouP. and 2 for each 
treated group . The re lative hype rplasiogenicity of these agents is: TPA > mezerein 
> 4-0-methyl TPA (400/1g) > EPP > phorbol dibenzoa te > 4-0 -methy l TPA (4 
I'g) > phorbo l. 
inhibiting TPA-stimulated DNA synthesis when it is applied at 
the same time as TP A (receptor level is high) . Therefore, we 
applied Dex (25 jlg) topically to the dorsal skin of mice either 
at the same time as TP A or 6 hI' after TP A, and assessed the 
rate of DNA synthesis. The results are presented in Table IV. 
When Dex is applied to the skin at the same time as TP A it 
inhibits the incorporation of ['JH]-thymidine into epidermal 
DNA to a significantly greater extent than when Dex is applied 
after TP A. These data demonstrate that the epidermis is less 
sensitive to inhibitory influences of GCs after application of 
TPA. 
Effect of Other Tumor Promoters an.d Hypelplasiogenic 
Agents on Epidermal GC Receptor Levels 
Although epidermal GC receptor levels are reduced after 
application of TPA, an important question is whether this 
reduction is a specific marker of tumor promotion or a general 
marker of hyperplasia. Several tumor-promoting and hyperpla-
siogenic agents were applied to the dorsal skin of mice; the 
concentration of epidermal cytosol GC receptors was deter-
mined 24 hr after application of the agents. A comparison of 
the effects of these agents is presented in Table V. Phorbol 
dibenzoate is a weaker tumor promoter than TP A, with weak 
to moderate activity [17]. At a dose of 4 p.g of phorbol djben-
zoate, GC receptor levels were reduced by 21%. 4-0-methyl 
TP A, which is not a complete promoter but is a first-stage 
tumor promoter [18], had no effect on GC receptor levels at a 
dose of 4 jlg (nonhyperplasiogenic); however, if the dose was 
increased to 400 p.g (hyperplasiogenic), the GC receptor levels 
were reduced by 50%. After application of mezerein (2 jlg)-a 
weak complete tumor promoter but a very potent hyperplasi-
ogenic agent [19] and second-stage promoter [18]-epidermal 
GC receptor levels were reduced by 50%. EPP (27 mg), a 
non promoting hyperpiasiogenjc agent, decreased epidermal GC 
receptor levels by 57%. Phorbol (4 jlg) had no significant effect. 
These results demonstrate that hyperplasiogenic agents are as 
effective as TP A in reducing the concentration of epidermal GC 
receptors, and weak tumor promoters are less effective than 
TPA. 
DISCUSSION 
The results presented here demonstrate the presence of a 
specific Dex binding component in adult mouse epidermal 
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cytosol ident ified as a GC receptor. This binding component is 
satw-able, has a hlgh affinity, and specifically binds both natw-al 
a nd synthetic GCs. GC recept01's have been identified in most 
mammalian tissues, including liver, lung, thymus, and fetal skin 
[20,21). The level of GC receptors in t hese t issues is comparable 
to that observed by us in adult mouse epidermis. Previous 
observations on the inhibition of epidermal cell proliferation by 
GCs [4-6J, along with ow- observations on the presence of GC 
receptors, establish t he epidermis as a specific target for GCs. 
Although TP A does not have a direct effect on GC receptors 
when added to the incubation mixtw-e for the binding assay, 
t here is a marked transient reduction in the level of epidermal 
cytosol GC receptors after a single application of TP A to the 
dorsal skin of SEN CAR mice. A maximum effect is observed 6-
24 hr after application of the tumor promoter. Fluocinolone 
acetonide, a very potent synthetic a nti-inflammatory agent 
(GC) , is less able to inhibit DNA synthesis in epidermis if it is 
applied 24 hI' after TP A than if it is applied to untreated skin 
[6,10J. This difference in the inhlbitory effect of th e GC on 
D NA synthesis correlates with the difference in the level of 
epidermal GC receptors in untreated and TP A-treated skin. 
Our results also show that Dex applied to th e skin after TP A 
inhibits DNA synthesis in the epidermis to a significantly lesser 
d egree than when it is applied at the same time as TP A. 
Other investigators have demonstrated tha t the loss of cyto-
p lasmic GC receptors leads to the loss of responsiveness to GCs. 
Mouse lymphoma and thymoma cell line variants selected for 
GC resistance have very low levels of GC receptors compared 
to the sensitive parent cell lines [22-25). Approximately 80% of 
t he resistant clones were deficient in cytoplasmic GC receptors 
a nd t he resistance correlated extremely well with the amou nt 
of cytoplasmic GC receptor [24,25]. A lack of correlation of 
cytoplasmic receptor level with resistance to GCs was demon-
s trated, but GC receptor .levels in these val'iants was within 
normal range and the defect was found to be in nuclear trans-
location [23,24). Thus these investigators did not observe nor-
mal GC responsiveness in variants deficient in GC receptor 
levels. A lack of correlation between GC receptor levels and 
I'esponse to GCs has also been observed in lymphoblast from 
]lUman leukemic patients but only in those patients who had 
r eceptor levels> 4000 sites/ cell and not in th ose who had 
I'eceptor levels < 4000 sites/ cell [26]. Thus t he transient de-
crease in t he level of GC receptors in epidel'mal cells migh t be 
a mechanism by which decreased sensitivity to GCs may be 
m ediated . 
It may be specula ted that the reduction in the level of GC 
r eceptors in epidermal cells after TP A application may provide 
a functionally permissive system in which TP A can induce 
hyperplasia. After application of a tumor promoter, there is an 
initial decrease in DNA synthesis dw-ing the first 6 hr, followed 
by an increase which peaks at 18-24 ill' [27). The peak in DNA 
synthesis is preceded by at least 12 hr dw-ing which GC receptor 
levels are very low. Consequently, if endogenous GCs do act on 
epidermal cells, as suggested by the data presented by Trainin 
[8], then because there al'e fewer receptors, these cells al'e less 
sensitive to GCs following exposure to TP A. It has also been 
demonstrated that after TP A application, epidermal cells lose 
their sens itivity to G, chalone, a protein that inhibits DNA 
synthesis [28]. GCs are capable of prolonging the chalone effect 
of epidermal cells [29). Thus, the decreased sensitivity of epi-
dermal cells to chalone and GCs after application of TPA may 
be related. 
Although we have demonstrated that the level of epidermal 
GC receptors is reduced after application of TP A to the skin, 
other agents that al'e not tumor promoters or are weak tumor 
promoters but potent hyperplasiogens ar e just as effective as 
TP A in caus ing a reduction in GC receptors. M ezerein is a very 
potent h yperplasiogen , a weak complete tumor promoter [19] , 
a nd a very effective second-stage tumor promoter [18]. The 
non promoting hyperplasiogenic agent EPP appeal's to be an 
effective t hird-stage promoter in a 3-stage promotion protocol 
(Slaga, unpublished results) and 4-0-methyl TP A is an effective 
fU'st-stage tumor promoter [18). Although th e reduction in the 
level of GC receptors is not a tumor promotion-specific event, 
it is an event related to the induction of hyperplasia. Further-
more, it must be emphasized that there is a strong correlation 
between phorbol ester-induced tumor promotion and hyperpla-
sia [17] and that agents such as mezerein, EPP, and 4-0-methyl 
TP A are not complete tumor promoters but are effective in a 
multiple-stage promotion protocol. 
The mechanism by whlch TP A brings about a reduction in 
the level of GC receptors is not known, but TP A acting as an 
antagonist that binds irreversibly to the receptors has been 
ruled out. There are other means thI'ough which TP A may act. 
For example TP A may in some way inhibit biosynthesis of the 
receptor protein. It has been proposed that th e GC receptor-
hormone complex, after binding to chI'omat in, is recycled 
through the cytoplasm, at which t ime it is rephosphorylated 
before it may again bind a steroid molecule [30]; TP A may 
prevent recycling or the phosphorylation step. TP A also in-
duces proteases in epidermal cells [31], whlch m ay degrade the 
receptOl". By whatever means TP A and other hyperplasiogenic 
agents bring about the reduction in the level of GC receptors, 
we propose that this event leads to a r eduction in the sensitivity 
of epidermal cells to endogenous GCs; thus, tumor -promoting 
or hyperplasiogenic agents are more effective in stinlUlating 
proliferation of cells less sensitive (or more resistant) to endog-
enous inhibitors. 
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A Technique for Immunoultrastructural Identification of T6-Positive 
Langerhans Cells and Indeterminate Cells in Mycosis Fungoides 
COLIN A. HOLDEN, B.Sc, M.B., M.R.C.P., EMYR W. MORGAN, B.Sc., AND 
DONALD M. MACJ)ONALD, M_A., M.B., F.R.C.P. 
Laboratory of Applied Dermatology, Guy's Hospital, London, Englan.d 
An immunoelectron microscopic method was devel-
oped using T6 antiserum in an immunoperoxidase tech-
nique to label the dendritic cells of the epidermis in 
mycosis fungoides (MF). The technique allows simulta-
neous identification of intracellular Birbeck granules 
and T6 membrane positivity. mtrastructural examina-
tion of the epidermal infiltrate of MF, using this method, 
confirmed the T6-positive nature of Langerhans cells 
and inde terminate cells. All Sezariform and mature lym-
phocytes wer~T6-negative and a small population ofT6-
negative histiocytic cells were also observed. 
The infiltrate of mycosis fungoides (MF) has been chru'acter-
ized immunohistochemically both in cases with systemic in-
volvement [1] and in cases restricted to the skin [2] to show a 
predominance of T helper lymphocytes. Other cell populations, 
including Langerhans cells [3] and his tiocytes [4,5], have been 
implicated in the pathogenesis ofMF. 
To date, Langerhans cells have been definitively character-
ized by the presence of cytoplasmic organelles termed Birbeck 
granules, which are identifiable on ultrastructural examination 
Manuscript J'eceived December 7, 1981; accepted for publication 
April 12, 1982 
Reprin t requests to: Dr. D. M. MacDonald, Department of Derma-
tology, Guy's Hospital, St. Thomas' Street, London, SE1 9RT, England. 
Abbreviations: 
MF: mycosis fungoides 
MNP: mononuclear phagocyte 
NSS: normal swine serum 
PBS: phosphate-buffered saline 
[6]. However, T6, a thymocyte-specific monoclonal antiserum 
cross-reacts with Langerhans cells [7] and, in the cutaneous 
lesions of MF, numerous dendritic T6-positive cells are ob-
served [2,3]. 
We have developed an immunoelectron peroxidase technique 
to allow simultaneous visualization of T6 membrane positivity 
and intracellulru' BU'beck granules, thus confu-ming at an ultra-
structural level the Langerhans cell and indeterminate cell 
nature of T6-positive cells. 
MATERIALS AND METHODS 
Tissue 
Elliptical skin biopsies of lesional skin were obtained from 5 patien ts 
with tumor-stage MF. A portion of each biopsy was processed for 
examination of routine hematoxylin and eosin (H&E) stained sections 
to confirm histologically the diagnosis. A fur ther piece of each biopsy 
was snap-frozen in liquid nitrogen and stored at -70°C for preliminary 
light microscopic studies. The major part of the biopsy was fixed for 
immunoelectron microscopy using 3% pamformaldehyde wi th 8.5% 
sucrose in phosphate-buffered saline (PBS) , for 4 I'll', washed in 8.5% 
sucrose in PBS overnight, and finally frozen and stored at -70°C. 
An.tisera 
OKT6 (Ortho Phru'maceuticals Ltd.) was diluted 1:6 in 1:5 normal 
swine serum (NSS): PBS. Fab-Po (sheep) antimouse Ig (Institu t Pas-
teu.r) was diluted 1: 15 in NSS. 
Controls 
Omission of the primary antiserum, substitution of the conjugate by 
Fab-Po (sheep) antirabbit Ig (lnstitut PasteuJ') , and the use of '3'3-
diaminobenzidine and hydl'Ogen peroxide alone were employed as con-
trols. 
